CorMedix (CRMD) Director Exercises Options and Executes Same-Day Sale

Rhea-AI Filing Summary

Alan W. Dunton, a director of CorMedix Inc. (CRMD), reported same-day transactions on 09/12/2025 in the company's common stock and related options. He exercised a stock option with a $3.55 exercise price to acquire 10,000 shares, increasing his direct holdings to 50,250 shares, and sold 10,000 shares the same day in multiple trades at a weighted average price of $13.13, reducing his direct holdings to 40,250 shares. The Form 4 discloses the option grant date of 03/05/2024 and that those options vest monthly with full vesting one year after grant. The filing is signed and dated 09/16/2025.

Positive

• Option exercise disclosed with exercise price of $3.55
• Sale price disclosed as a weighted average of $13.13, with execution price range provided
• Vesting schedule disclosed for options granted 03/05/2024 with monthly vesting and full vesting at one year

Negative

• Direct beneficial ownership decreased from 50,250 to 40,250 shares after the reported sale

Insights

Securities Analyst

TL;DR: Director exercised options and sold the same number of shares, realizing proceeds while retaining significant ownership.

The reporting shows an option exercise at a $3.55 strike and an immediate sale at a weighted average of $13.13, indicating the director realized a material per-share spread of about $9.58 before costs and taxes. Direct beneficial ownership fell from 50,250 to 40,250 shares after the transactions, while 10,000 option shares remain exercisable, yielding total direct plus derivative exposure of 20,000 option-based shares and 40,250 common shares. For investors, these are routine Section 16 transactions reflecting liquidity-taking by an insider rather than a change in control or new strategic position.

Corporate Governance Expert

TL;DR: Transactions are standard insider exercises and sales; disclosure is timely and properly documented.

The Form 4 lists the director status and provides required details: transaction codes, quantities, prices, option grant and vesting terms, and an explanatory footnote on trade prices. The reporting person checked the box indicating individual filing. The signature and date are present. From a governance perspective, documentation appears complete and transparent for these non-derivative and derivative changes, with no additional governance actions or disclosures evident in the filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

DUNTON ALAN W

(Last) (First) (Middle)

C/O CORMEDIX INC.,

300 CONNELL DRIVE, SUITE 4200

(Street)

BERKELEY HEIGHTS NJ 07922

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [ CRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/12/2025		M		10,000	A	$3.55	50,250	D
Common Stock	09/12/2025		S		10,000	D	$13.13(1)	40,250	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Common Stock)	$3.55	09/12/2025		M			10,000	(2)	03/05/2034	Common Stock	10,000	$0	20,000	D

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $13.00 to $13.25. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

2. These options were granted on 3/5/2024. The options vest monthly with full vesting on the one year anniversary of the date of grant, subject to continued service on the board.

	/s/ Alan W. Dunton	09/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did CRMD director Alan W. Dunton report on Form 4?

He reported an exercise of 10,000 option shares at a $3.55 exercise price and a sale of 10,000 common shares on 09/12/2025.

What price did Alan W. Dunton receive when selling CRMD shares?

The sale was executed in multiple trades at prices ranging from $13.00 to $13.25, with a reported weighted average sale price of $13.13.

How did these transactions affect Dunton's ownership in CRMD?

After the exercise and sale, Dunton's direct beneficial ownership stood at 40,250 shares; it had been 50,250 immediately after the exercise.

When were the options granted and what are the vesting terms?

The options were granted on 03/05/2024 and vest monthly with full vesting on the one-year anniversary, subject to continued board service.

When was the Form 4 signed and filed?

The form is signed by Alan W. Dunton and dated 09/16/2025.